Literature DB >> 20978037

Disease progression in multiple sclerosis: combining physicians' and patients' perspectives?

J J Kragt1, J M Nielsen, F A H van der Linden, C H Polman, B M J Uitdehaag.   

Abstract

BACKGROUND: To assess disease progression in multiple sclerosis (MS) several outcome measures are available. The interrelation of changes on different scales has not been studied extensively and the concept of combining scales has only recently been introduced in MS.
OBJECTIVE: To explore combining different clinical outcome measures in the evaluation of disease progression in MS.
METHODS: In 553 patients we studied the presence of relevant changes according to standard definitions on the Expanded Disability Status Scale (EDSS), Nine-Hole Peg Test (9HPT), Timed 25-Foot Walk (T25FW) and the Multiple Sclerosis Impact Scale (MSIS-29). We examined 'exclusive worsening' (worsening on one measure while not worsening on any other measure) and 'opposing changes' (worsening on one measure while improving on another measure). Finally, we investigated the impact of combining assessments.
RESULTS: Based on the EDSS alone, 140 patients progressed. However, almost twice as many (275) showed worsening on any of the clinical outcome measures. Exclusive worsening was observed in 37 patients on the EDSS, 13 on the 9HPT, 39 on the T25FW and 44 on the MSIS physical. Of all worsened patients 76 (28%) showed opposing changes, a phenomenon predominantly observed when combining physician-based and patient-derived outcome measures.
CONCLUSION: When assessing disease progression in MS, sensitivity to change can be increased by combining different outcome measures. The added value is especially present when combining measures from different perspectives. However, further research is needed to evaluate the optimal way to combine outcome measures before implementing this strategy in clinical studies.

Entities:  

Mesh:

Year:  2010        PMID: 20978037     DOI: 10.1177/1352458510385505

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  5 in total

1.  Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.

Authors:  Omid Beiki; Paolo Frumento; Matteo Bottai; Ali Manouchehrinia; Jan Hillert
Journal:  JAMA Neurol       Date:  2019-06-01       Impact factor: 18.302

2.  Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Authors:  Gavin Giovannoni; Jeffrey A Cohen; Alasdair J Coles; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; David H Margolin; Stephen L Lake; Susan M Kaup; Michael A Panzara; D Alastair S Compston
Journal:  Neurology       Date:  2016-10-12       Impact factor: 9.910

3.  Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression.

Authors:  Jeri Burtchell; Kristen Fetty; Katelyn Miller; Kit Minden; Daniel Kantor
Journal:  Neurol Ther       Date:  2019-07-04

Review 4.  Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives.

Authors:  Elisabeth G Celius; Heidi Thompson; Maija Pontaga; Dawn Langdon; Alice Laroni; Stanca Potra; Trishna Bharadia; David Yeandle; Jane Shanahan; Pieter van Galen; Nektaria Alexandri; Jürg Kesselring
Journal:  Patient Prefer Adherence       Date:  2021-01-08       Impact factor: 2.711

5.  Anorectal dysfunction in multiple sclerosis: a systematic review.

Authors:  Sanober Nusrat; Elsie Gulick; David Levinthal; Klaus Bielefeldt
Journal:  ISRN Neurol       Date:  2012-07-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.